Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
4.850
+0.700 (16.87%)
At close: Mar 17, 2026, 4:00 PM EDT
6.04
+1.19 (24.54%)
After-hours: Mar 17, 2026, 5:31 PM EDT
Artelo Biosciences Employees
Artelo Biosciences had 7 employees as of December 31, 2025. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change
1
Growth
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,839,857
Market Cap
10.31M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7 | 1 | 16.67% |
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 40 |
| Imunon | 25 |
| Theriva Biologics | 22 |
| SeaStar Medical Holding | 19 |
| Quantum BioPharma | 17 |
| Iterum Therapeutics | 9 |
| Akari Therapeutics, | 9 |
| Aprea Therapeutics | 8 |
ARTL News
- 11 days ago - Artelo Biosciences Announces Reverse Stock Split - GlobeNewsWire
- 21 days ago - Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results - GlobeNewsWire
- 3 months ago - Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate - GlobeNewsWire
- 4 months ago - Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - GlobeNewsWire
- 5 months ago - Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - GlobeNewsWire
- 5 months ago - Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit - GlobeNewsWire
- 5 months ago - Artelo Biosciences Announces Closing of $2.0 Million Public Offering - GlobeNewsWire